CIABATTI, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 2.756
EU - Europa 1.578
AS - Asia 759
SA - Sud America 96
AF - Africa 72
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 5.265
Nazione #
US - Stati Uniti d'America 2.683
IT - Italia 574
CN - Cina 408
SE - Svezia 373
SG - Singapore 158
GB - Regno Unito 152
DE - Germania 149
BG - Bulgaria 133
BR - Brasile 85
CA - Canada 68
VN - Vietnam 64
TR - Turchia 56
RU - Federazione Russa 52
CI - Costa d'Avorio 46
FI - Finlandia 41
HK - Hong Kong 27
FR - Francia 26
BE - Belgio 24
UA - Ucraina 21
IN - India 20
SN - Senegal 13
JP - Giappone 10
ES - Italia 7
NG - Nigeria 7
CZ - Repubblica Ceca 5
NL - Olanda 5
EC - Ecuador 4
GR - Grecia 4
KR - Corea 4
CH - Svizzera 3
PK - Pakistan 3
AT - Austria 2
AU - Australia 2
CO - Colombia 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
PL - Polonia 2
PR - Porto Rico 2
TN - Tunisia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BJ - Benin 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
ID - Indonesia 1
IE - Irlanda 1
IQ - Iraq 1
IR - Iran 1
JM - Giamaica 1
LT - Lituania 1
MA - Marocco 1
MX - Messico 1
PA - Panama 1
PY - Paraguay 1
TW - Taiwan 1
UY - Uruguay 1
Totale 5.265
Città #
Serra 274
Fairfield 272
Woodbridge 270
Santa Clara 259
Chandler 236
Houston 206
Ann Arbor 205
Ashburn 151
Sofia 131
Seattle 128
Beijing 119
Shanghai 111
Wilmington 101
New York 87
Cambridge 85
Boardman 78
Princeton 70
Singapore 65
Ottawa 64
Milan 57
Medford 47
Abidjan 46
Lawrence 44
Florence 39
London 38
Des Moines 37
Lancaster 28
Bremen 27
Dearborn 27
Izmir 26
Hong Kong 25
Pisa 24
Nanjing 23
Brussels 22
Istanbul 22
San Diego 20
Jacksonville 17
Dong Ket 15
Rome 14
Dakar 13
Shenyang 13
Nanchang 12
Fuzhou 11
Alessandria 10
Hebei 9
Redwood City 9
Council Bluffs 8
Duncan 8
Kunming 8
Los Angeles 8
Monza 8
Hefei 7
Lagos 7
Nuremberg 7
Washington 7
Düsseldorf 6
Frankfurt am Main 6
Kocaeli 6
Ogden 6
São Paulo 6
Changsha 5
Hangzhou 5
Helsinki 5
Jiaxing 5
Palermo 5
Phoenix 5
Westminster 5
Boulder 4
Campinas 4
Chicago 4
Guangzhou 4
Livorno 4
Pune 4
Quanzhou 4
Turin 4
Bern 3
Dallas 3
Detroit 3
Guarulhos 3
Ho Chi Minh City 3
Hortolândia 3
Jüchen 3
Kent 3
Kilburn 3
Leawood 3
Nürnberg 3
Rio de Janeiro 3
Selargius 3
Taranto 3
Trento 3
Wuhan 3
Boston 2
Capannori 2
Chengdu 2
Curitiba 2
Garanhuns 2
Guayaquil 2
Harbin 2
Jinan 2
Leeds 2
Totale 3.818
Nome #
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 197
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study 189
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 157
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 155
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 149
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 144
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 140
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 138
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 136
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 135
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 134
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 134
MDS: An Integrated Workup for a Correct Diagnosis 128
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 128
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 128
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 127
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 121
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 120
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 118
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 118
Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia 115
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 115
Combined FAMD and ANOVA investigation leads to significant association between the hOCT1/ABCB1 diplotype and both efficacy and tolerability in patients affected by chronic myeloid leukemia 110
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 107
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation 106
WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes 105
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line 101
Donor-transmitted Triple-Hit Lymphoma in a Renal Allograft Recipient 100
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 100
Cell clonality in hypereosinophilic syndrome: what pathogenetic role? 94
Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation 92
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 88
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 88
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 88
Conventional Cytogenetics, ACGH, and PCR as Integrated Workup for a Correct Diagnosis of MDS 86
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 82
R-IPSS, RPS14 AND WT1 LEVELS ARE THE BEST PROGNOSTIC FACTORS FOR PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES DURING AZACITIDINE TREATMENT. 81
Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS) 80
THE C.480C>G POLYMORPHISM OF HOCT1 TRANSPORTER INFLUENCES IMATINIB CLEARANCE IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 77
Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation 72
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms 70
TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA 66
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.sinensis leaf extract. 64
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study 59
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 59
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms 58
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 57
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: Correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 57
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 55
Human mesenchymal cells inhibit IL2 and zoledronate-induced gamma/delta T-cells 54
Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation 53
null 51
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network 37
Totale 5.423
Categoria #
all - tutte 16.335
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.335


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020352 0 0 0 0 0 0 0 60 71 89 90 42
2020/2021368 27 17 22 15 26 22 21 26 43 31 39 79
2021/2022670 15 32 12 39 111 92 24 17 70 28 53 177
2022/2023863 133 164 53 72 71 94 8 67 124 15 57 5
2023/2024494 55 39 66 31 52 86 28 12 6 19 24 76
2024/2025797 6 60 11 99 198 202 174 47 0 0 0 0
Totale 5.423